GlaxoSmithKline, CureVac Join Forces on mRNA Vaccine Effort
GlaxoSmithKline (GSK) and CureVac have entered a strategic collaboration for research and commercialization of five messenger RNA-based vaccines and monoclonal antibodies for infectious diseases.
GSK will make a $164 million investment in CureVac, representing a 10 percent stake in the company, as well as make a $131 million upfront payment. GSK will also make a one-time reimbursable payment of $32 million to reserve manufacturing capacity.
CureVac’s existing mRNA-based COVID-19 vaccine program is not included in this collaboration.